Skip to Content

'
Jeri Kim, M.D.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1993 University of Southern California, School of Medicine, Los Angeles, CA, MD, Medicine
1988 University of California Los Angeles, Los Angeles, CA, BS, Biochemistry

Board Certifications

2006 Medical Oncology
1996 American Board of Internal Medicine

Experience/Service

Academic Appointments

Associate Member, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX, 9/2010-present
Member, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX, 8/2006-8/2010
Assistant Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 1999-2005

Administrative Appointments/Responsibilities

Director, Department of Genitourinary Medical Oncology - Research Biorepository, The University of Texas MD Anderson Cancer Center, Houston, TX, 1999-present

Honors and Awards

2005 Participation in AACR Task Force on Prevention Meeting
2004 Incentive Salary Award
2001-2004 Clinician Investigator Program Career Development Award
2001 Institutional Research Grant Award
1998 Clinical Fellows Research Award
1998 Participation in ASCO/AACR Methods in Clinical Cancer Research, Third Annual Workshop
1997 Clinical Fellows Research Award
1996-1997 Clifton D. Howe Award for Clinical Excellence
1990-1991 Fifth Year Research Scholar, Experimental Cutaneous Injury Due to Hydrofluoric Acid
1987 National Science Foundation Summer Research Fellowship: Organic Chemistry
1984-1988 Dean's Honor List, University of California, Los Angeles

Selected Publications

Peer-Reviewed Original Research Articles

1. Logothetis CJ, Gallick GE, Maity SN, Kim J, Aparicio A, Efstathiou E, Lin SH. Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer. Cancer Discov 3(8):849-61, 8/2013. e-Pub 6/28/2013. PMID: 23811619.
2. Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, Pagliaro LC, Kim J, Millikan RE, Ryan C, Tannir NM, Zurita AJ, Mathew P, Arap W, Troncoso P, Thall PF, Logothetis CJ. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res 19(13):3621-30, 7/1/2013. e-Pub 5/6/2013. PMCID: PMC3699964.
3. Bilen MA, Kim J, Wang H, Tu SM. Cituxumumab-associated pancolitis in a patient with prostate cancer. Clin Genitourin Cancer 11(2):207-10, 6/2013. e-Pub 10/17/2012. PMCID: PMC3579009.
4. Kim J, Ebertowski J, Janiga M, Arzola J, Gillespie G, Fountain M, Soderdahl D, Canby-Hagino E, Elsamanoudi S, Gurski J, Davis JW, Parker PA, Boyd DD. Many young men with prostate-specific antigen (PSA) screen-detected prostate cancers may be candidates for active surveillance. BJU Int 111(6):934-40, 5/2013. e-Pub 1/25/2013. PMCID: PMC3637421.
5. del Junco DJ, Fox EE, Cooper S, Goldhagen M, Koda E, Rogers D, Canby-Hagino E, Kim J, Pettaway C, Boyd DD. Increasing low risk prostate cancer incidence in United States Air Force Servicemen and Selection of Treatments. J Urol 185(6):2137-2142, 6/2011. e-Pub 4/15/2011. PMCID: PMC3171171.
6. Li J, Ding Z, Wang Z, Lu JF, Maity SN, Navone NM, Logothetis CJ, Mills GB, Kim J. Androgen regulation of 5α-reductase isoenzymes in prostate cancer: Implications for prostate cancer prevention. PLoS One 6(12):e28840, 2011. e-Pub 12/14/2011. PMCID: PMC3237548.
7. Davis JW, Kim J, Ward JF, Wang X, Nakanishi H, Babaian RJ, Troncoso P. Radical prostatectomy findings in patients with low-volume/low-risk prostate cancer diagnosed by extended core biopsies:an analysis of tumor volume and zonal distribution of tumour foci. BJU Int 105(10):1386-91, 5/2010. e-Pub 11/3/2009. PMID: 19888979.
8. Li J, Kim J. Molecular profiles of finasteride effects on prostate carcinogenesis. Cancer Prev Res (Phila) 2(6):518-24, 6/2009. e-Pub 6/2/2009. PMID: 19491289.
9. Blando J, Portis M, Benavides F, Alexander A, Mills G, Dave B, Conti CJ, Kim J, Walker CL. PTEN deficiency is fully penetrant for invasive prostate adenocarcinoma in C57B/6 mice. Am J Pathol 174(5):1869-79, 5/2009. PMCID: PMC2671275.
10. Tsavachidou D, McDonnell TJ, Wen S, Wang X, Vakar-Lopez F, Pisters LL, Pettaway CA, Wood CG, Do KA, Thall PF, Stephens C, Efstathiou E, Taylor R, Menter DG, Troncoso P, Lippman SM, Logothetis CJ, Kim J. Selenium and Vitamin E:Cell Type-and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst 101(5):206-20, 3/4/2009. e-Pub 2/24/2009. PMCID: PMC2734116.
11. Lin SH, Lee YC, Choueiri MB, Wen S, Mathew P, Ye X, Do KA, Navone NM, Kim J, Tu SM, Yu-Lee LY, Logothetis CJ. Soluble ErbB3 levels in bone marrow and plasma in men with prostate cancer. Clin Cancer Res 14(12):3729-36, 6/15/2008. PMCID: PMC2562877.
12. Jonasch E, Wood C, Tamboli P, Pagliaro LC, Tu SM, Kim J, Srivastava P, Perez C, Isakov L, Tannir N. Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine:clinical finds. Brit J Cancer 98(8):1336-41, 3/2008. PMID: 18362942.
13. Lin SH, Cheng CJ, Lee YC, Ye X, Tsai WW, Kim J, Pasqualini P, Arap W, Navone NM, Tu SM, Hu M, Yu-Lee LY, Logothetis CJ. A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation. Oncogene 27(39):5195-203, 2008. PMID: 18490922.
14. Mao S, Daliani DD, Wang X, Thall PF, Do KA, Perez CA, Brown MA, Bouchillon K, Carter CM, Logothetis CJ, Kim J. Employing the treatment-free interval of intermittent androgen ablation to screen candidate prostate cancer therapies. Prostate 67(15):1677-85, 11/1/2007. PMID: 17879948.
15. Cheng CJ, Ye XC, Vakar-Lopez F, Kim J, Tu SM, Chen DT, Navone NM, Yu-Lee LY, Lin SH, Hu MC. Bone microenvironment and androgen status modulate subcellular localization of ErbB3 in prostate cancer cells. Mol Cancer Res 5(7):675-84, 7/2007. PMCID: PMC2000833.
16. Subbarayan V, Krieg P, His LC, Kim J, Yang P, Sabichi AL, Llansa N, Mendoza G, Logothetis CJ, Newman RA, Lippman SM, Menter DG. 15-lipoxygenase-2 (15-LOX-2) gene regulation by its product 15-S-hydroxyeicostatetraenoic acid through a negative feed back mechanism that involves peroxisome proliferators-activated receptor gamma. Oncogene 25(44):6015-25, 9/2006. PMID: 16682954.
17. Kelloff GJ, Lippman SM, Dannenberg AJ, Sigman CC, Pearce HL, Reid BJ, Szabo E, Jordan VC, Spitz MR, Mills GB, Papadimitrakopoulou VA, Lotan R, Aggarwal BB, Bresalier RS, Kim J, Arun B, Lu KH, Thomas ME, Rhodes HE, Brewer MA, Follen M, Shin DM, Parnes HL, Siegfried JM, Evans AA, Blot WJ, Chow WH, Blount PL, Maley CC, Wang KK, Lam S, Lee JJ, Dubinett SM, Engstrom PF, Meyskens FL, O'Shaughnessy J, Hawk ET, Levin B, Nelson WG, Hong WK, AACR Task Force on Cancer Prevention. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia (IEN) and cancer--a plan to move forward. Clin Cancer Res 12(12):3661-97, 6/15/2006. PMID: 16778094.
18. Tu SM, Kim J, Pagliaro LC, Vakar-Lopez F, Wong FC, Wen S, General R, Podoloff DA, Lin SH, Logothetis CJ. Strontium-89 combined with chemotherapy does not compromise subsequent tharapy in selected patients with androgen-independent prostate cancer. J Clin Oncol 23(31):7904-10, 11/1/2005. PMID: 16258090.
19. Lee SH, Nishino M, Mazumdar T, Garcia GE, Galfione M, Lee FL, Lee CL, Liang A, Kim J, Feng L, Eissa NT, Lin SH, Yu-Lee LY. Antiangiogenic effect of 16-kDa prolactin involves the inhibition of the IRF-1 pathway that regulates iNOS expression. Cancer Res 65(17):7984-92, 9/1/2005. PMID: 16140971.
20. Kim J, Yang P, Suraokar M, Sabichi AL, Llansa ND, Mendoza G, Subbarayan V, Logothetis CJ, Newman RA, Lippman SM, Menter DG. Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products. Cancer Res 65(14):6189-98, 7/15/2005. PMID: 16024620.
21. Kim J, Sun P, Lam YW, Troncoso P, Sabichi AL, Babaian RJ, Pisters LL, Pettaway CA, Wood CG, Lippman SM, McDonnell TJ, Lieberman R, Logothetis C, Ho SM. Changes in serum proteomic patterns by presurgical alpha-tocopherol and L-selenomethionine supplementation in prostate cancer (*co-first authors). Cancer Epidemiol Biomarkers Prev 14(7):1697-1702, 7/2005. PMID: 16030104.
22. Subbarayan V, Xu XC, Kim J, Yang P, Hoque A, Sabichi AL, Llansa N, Mendoza G, Logothetis CJ, Newman RA, Lippman SM, Menter DG. Inverse relationship between 15-lipoxygenase-2 and PPAR-gamma gene expression in normal epithelia compared with tumor epithelia. Neoplasia 7(3):280-93, 3/2005. PMCID: PMC1501140.
23. Subbarayan V, Sabichi AL, Kim J, Llansa N, Logothetis CJ, Lippman SM, Menter DG. Differential peroxisome proliferator-activated receptor-gamma isoform expression and agonist effects in normal and malignant prostate cells. Cancer Epidemiol Biomarkers Prev 13(11 Pt 1):1710-6, 11/2004. PMID: 15533897.
24. Fizazi K, Sikes CR, Kim J, Yang J, Martinez LA, Olive MC, Logothetis CJ, Navone NM. High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer. Anticancer Res 24(5A):2897-903, Sep-Oct, 9/2004. PMID: 15517894.
25. Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, Kim J, Adams J, Elliott P, Esseltine D, Petrusich A, Dieringer P, Perez C, Logothetis CJ. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 22(11):2108-21, 6/1/2004. PMID: 15169797.
26. Vakar-Lopez F, Cheng CJ, Kim J, Shi GG, Troncoso P, Tu SM, Yu-Lee LY, Lin SH. Up-regulation of MDA-BF-1, a secreted isoform of ErbB3, in metastatic prostate cancer cells and activated osteoblasts in bone marrow. J Pathol 203(2):688-95, 6/2004. PMID: 15141384.
27. Salas TR, Kim J, Vakar-Lopez F, Sabichi AL, Troncoso P, Jenster G, Kikuchi A, Chen SY, Shemshedini L, Suraokar M, Logothetis CJ, DiGiovanni J, Lippman SM, Menter DG. Glycogen synthase kinase-3 beta is involved in the phosphorylation and suppression of androgen receptor activity.(*co-first authors). J Biol Chem 279(18):19191-200, 4/30/2004. e-Pub 2/24/2004. PMID: 14985354.
28. Tu SM, Millikan RE, Pagliaro LC, Daliani D, Papandreou CN, Kim J, Chen DT, Williams DL, Logothetis CJ. Treatment of refractory urothelial carcinoma with alternating paclitaxel, methotrexate, cisplatin (TMP) and 5-fluorouracil, alpha-interferon, cisplatin (FAP). Urol Oncol 21(5):342-8, Sep-Oct, 9/2003. PMID: 14670540.
29. Galfione M, Luo W, Kim J, Hawke D, Kobayashi R, Clapp C, Yu-Lee LY, Lin SH. Expression and purification of the angiogenesis inhibitor 16-kDa prolactin fragment from insect cells. Protein Expr Purif 28(2):252-8, 4/2003. PMID: 12699689.
30. Kim J, Luo W, Chen DT, Earley K, Tunstead J, Yu-Lee LY, Lin SH. Antitumor activity of the 16-kDa prolactin fragment in prostate cancer. Cancer Res 63(2):386-93, 1/15/2003. PMID: 12543792.
31. Mintz PJ, Kim J, Do KA, Wang X, Zinner RG, Cristofanilli M, Arap MA, Hong WK, Troncoso P, Logothetis CJ, Pasqualini R, Arap W. Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat Biotechnol 2(1):57-63, 1/2003. e-Pub 12/23/2002. PMID: 12496764.
32. Kim J, Millikan RE, Smith TL, Tu SM, Pagliaro LC, Logothetis CJ. Treating refractory advanced or metastatic urothelial carcinoma with interleukin-2: a phase II study. Urol Oncol 21(1):21-6, Jan-Feb, 1/2003. PMID: 12684123.
33. Zinner RG, Kim J, Herbst RS. Non-small cell lung cancer clinical trials with trastuzumab: their foundation and preliminary results. Lung Cancer 37(1):17-27, 7/2002. PMID: 12057863.
34. Fizazi K, Prow DM, Do KA, Wang X, Finn L, Kim J, Daliani D, Papandreou CN, Tu SM, Millikan RE, Pagliaro LC, Logothetis CJ, Amato RJ. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours. Br J Cancer 86(10):1555-60, 5/2002. PMID: 12085204.
35. Tu SM, Millikan RE, Mengistu B, Delpassand ES, Amato RJ, Pagilaro LC, Dailani D, Papandreou CN, Smith TL, Kim J, Podoloff DA, Logothetis CJ. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate:a randomized phase II trial. Lancet 357:336-41, 2001. PMID: 11210994.
36. Kim J, Palmer JL, Finn L, Hodges S, Bowes VV, Deftos L, Murphy G, Logothetis C. The pattern of serum markers in patients with androgen-independent adenocarcinoma of the prostate. Urol Oncol 5(3):97-103, 4/2000. PMID: 10765015.
37. Newman RA, Kim J, Newman BM, Bruno R, Bayssas M, Klink-Alaki M, Pazdur R. Phase I trial of intoplicine (RP 60475) administered as a 72 h infusion every 3 weeks in patients with solid tumors. Anticancer Drugs 10(10):889-94, 11/1999. PMID: 10630356.
38. Kim J, Logothetis CJ. Serologic tumor markers, clinical biology, and therapy of prostatic carcinoma. Urol Clin North Am 26(2):281-90, 5/1999. PMID: 10361551.
39. Kim J, Zhi J, Satoh H, Koss-Twardy SG, Passe SM, Patel IH, Pazdur R. Pharmacokinetics of recombinant human interferon-alfa 2a combined with 5-fluorouracil in patients with advanced colorectal carcinoma. Anticancer Drugs 9(8):689-96, 9/1998. PMID: 9823427.
40. Hjelle B, Goade D, Torrez-Martinez N, Lang-Williams M, Kim J, Harris RL, Rawlings JA. Hantavirus pulmonary syndrome, renal insufficiency, and myositis associated with infection by Bayou hantavirus. Clin Infect Dis 23(3):495-500, 9/1996. PMID: 8879771.
41. Kim J, Weibel TJ, Calobrace MB, Foldi JF, Zawacki BE. A standard experimental 'Chemical Burn'. Burns 20(3):200-1, 6/1994. PMID: 8054129.

Invited Articles

1. Li J, Amos CJ, Kim J. Role of 5a-reductase in prostate cancer prevention. Uro Today, 2012.
2. Kim J, Parker P, Boyd D. Should the low participation rate of young (less than 56 years) men with clinically insignificant prostate cancer in active surveillance be increased? Uro Today, 2011.
3. Zinner RG, Kim J, Herbst RS. Trastuzumab enters non-small cell lung cancer clinical trials. Her2 in Oncol 1(3):2-11, 2000.

Editorials

1. Kim J. Chemoprevention of prostate cancer: breakthroughs and controversies. Expert Rev Anticancer Ther 10(10):1517-22, 10/2010. PMID: 20942621.
2. Efstathiou E, Kim J, Logothetis CJ. Informative clinical investigation:a demanding task master. J Clin Oncol 27(30):4986-93, 10/20/2009. e-Pub 8/31/2009. PMID: 19720892.

Abstracts

1. Kim J, Ward JF, Pettaway CA, Wang S, Kuban DA, Frand SF, Lee A, Pisters LL, Matin SF, Shah JB, Karam JA, Chapin BF, Papadopoulos JN, Achim BF, Hoffman KE, Pugh TJ, Choi S, Logothetis C, Troncoso P, Davis JW. Risk of Missing advanced stage or high grade tumors during active surveillance (AS) even in favorable-risk prostate cancer (PC). Journal of Clinical Oncology, 2013 ASCO Annual Meeting Proceedings, 5/2013.
2. Kim J, Davis JW, Klein EA, Magi-Galluzzi C, Lotan Y, Ward JF, Pisters LL, Basler JW, Pettaway CA, Li Ning Tapia EM, Wang X, Do KA, Lee J, Vornik LA, Tangrea J, Parnes HL, Lippman SM, Thompson IM, Brown PH, Troncoso P, Logothetis CJ. A double-blind randomized controlled multisite trial evaluating tissue effects of preoperative finasteride in clinically organ-confined prostate cancer: Pathologic outcomes. Proceedings of the 104th Annual Meeting of the American Association for Cancer Research abstr 195, 4/2013.
3. Li Ning Tapia E, Kim J, Efstathiou E, Wang X, Prokhorova I, Gorlov I, Amos C, Troncoso P. Linking markers of steroid metabolism, cell cycle and microenvironment to Gleason Score: Towards the development of a prognostic panel. USCAP, 3/2013.
4. Hoffman KE, Niu J, Shen Y, Jiang J, Shah JB, Smith GL, Davis JW, Kim J, Volk R, Kuban DA, Giordano SH, Smith BD. Does the diagnosing urologist influence choice of initial active treatment vs. observation for older men with favorable prostate cancer?. GU ASCO, 2/2013.
5. Oh JH, Davis JW, Hoffman KE, Wen S, Taylor SH, Doshi S, Jakkoju R, Suman S, Day R, Kim J. Significance of Age and Comorbidity in Management Decision-Making in Early Stage Prostate Cancer. Societe Internationale d'Urologie Oncology Update, 10/2012.
6. Parker P, Ebertwoski J, Janiga M, Arzola J, Fountain M, Canby-Hagino E, Kim J, Boyd DD. Evaluating the factors contributing to the high rate of definitive treatment in Department of Defense (DoD) personnel diagnosed with low-risk prostate cancer. MD Anderson Cancer Survivorship Research Retreat, 1/2012.
7. Ebertwoski J, Janiga M, Arzola J, Gillispie G, Fountain M, Soderdahl D, Davis J, Kim J, Boyd DD. Is a subset of prostate-specific antigen screen-detected, prostate cancers cases diagnosed in servicemen under 56 years candidate for active surveillance?. MD Anderson Cancer Survivorship Research Retreat, 1/2012.
8. Davis JW, Troncoso PT, Ward JF, Pettaway CA, Pisters LL, Kuban D, Brown V, Logothetic C, Kim J. Active surveillance for clinically localized prostate cancer at a high volume tertiary referral center. Societe Internationale d'Urologie Oncology Update, 11/2008.
9. Davis JW, Kim J, Troncoso PT. Radical Prostatectomy findings in patients considered potential candidates for active surveillance. Societe Internationale d'Urologie Oncology Update, 11/2008.
10. Davis JW, Troncoso P, Ward J, Babian RJ, Pettaway C, Pisters L, Kuban D, Brown V, Logothetis C, Kim J. Active surveillance for clinically localized prostate cancer in the era of technology: Introduction of a prospective protocol into a high volume tertiary research center. 24th Annual European Association of Urology Congress, Poster Presentation, 2008.
11. Troncoso P, Davis JW, Ward JF, Wang X, Nakanishi H, Babaian RJ, Kim J. Radical prostatectomy findings in patients considered potential candidates for active surveillance. 97th United States and Canadian Academy of Pathology, Abstr #845, Oral Presentation, 2008.
12. Aparicio AM, Lin AM, Araujo JC, Logothetis CJ, Kim J, Pagliaro LC, Tu S, Guo C, Jones D, Thall P, Mathew P. Use of clinical features to select a chemotherapy-responsive variant of aggressive prostate cancer (PC), Abstract 16000. J Clin Oncology 26, 2008.
13. Lin SH, Kim J, Tunstead J, Chen DT, Luo W, Earley K, and Yu-Lee LY. Effectors of 16-kDa Prolactin in Endothelial Cells. The Endocrine Society's 85th Annual Meeting. Oral Presentation, 2003.
14. Kim J, Troncoso P, Thall PF, Wang X, Llansa N, Babaian RJ, Pisters LL, Pettaway CA, Wood CG, Johnson K, Taylor RJ, Menter DG, Lippman SM, Logothetis CJ, Lieberman R, Sabichi AL. Effects of vitamin E and selenium on plasma lipid peroxidation: Preliminary results from a randomized, controlled trial of selenium and vitamin E in preprostatectomy patients. Proceedings of the American Association for Cancer Research 44 (abstr 3905). Poster Presentation, 2003.
15. Mintz P, Kim J, Do KA, Wang X, Zinner RG, Cristofanilli M, Arap MA, Hong WK, Troncoso P, Logothetis CJ, Pasqualini R, Arap W. Fingerprinting the circulating repertoire of antibodies from cancer patients. Proceedings of the American Association for Cancer Research 44 (abstr 5629). Poster Presentation, 2003.
16. Fizazi K, Sikes CR, Yang J, Kim J, Martinez LA, Logothetis CJ, Navone NM. High efficacy of docetaxel in preclinical models of advanced prostate cancer with and without androgen ablation and estramustine. Proceedings of the American Association for Cancer Research 44 (abstr 810). Poster Presentation, 2003.
17. Lin SH, Tu SM, Vakar-Lopez F, Troncoso P, Earley K, Tunstead J, Kim J, Galfione M, McNally FJ, Hu M, Kobayashi R, Logothetis CJ. Identification of bone metastasis-related factors in the bone marrow supernatant from prostatic cancer patients. The IVth International Conference on Cancer-Induced Bone Diseases (p. 42, Oral Presentation Section), 2003.
18. Shi GG, Tu SM, Kim J, Earley K, Wang X, Logothetis C, Lin SH. Platelet-derived growth factor AB and BB in the bone marrow of prostate cancer patients with bone metastasis. The IVth International Conference on Cancer-Induced Bone Diseases (p. 45, Poster Abstracts). Poster Presentation, 2003.
19. Vakar-Lopez F, Cheng CJ, Kim J, Shi GG, Tunstead JR, Troncoso P, Ruggeri A, Tu SM, Lin SH. Up-regulation of soluble ErbB3 in metastatic prostate cancer cells and activated osteoblasts in bone marrow. The IVth International Conference on Cancer-Induced Bone Diseases (p. 19, Poster Abstracts). Poster Presentation, 2003.
20. Tu SM, Kim J, Wang X, Do KA, Earley K, Ruggeri A, Logothetis C, Lin SH. Validating insulin-like growth factor (IGF)-1 and IGF binding protein (IGFBP)-3 as pertinent therapeutic targets for advanced prostate cancer. The IVth International Conference on Cancer-Induced Bone Diseases (p. 50, Poster Abstracts). Poster Presentation, 2003.
21. Kim J, Sabichi AL, Troncoso P, Babaian RJ, Pisters LL, Pettaway CA, Wood CG, Thall PF, Johnson K, Menter DG, Lippman SM, Logothetis CJ, Lieberman R. A preoperative model for testing chemopreventive agents in prostate cancer. Proceedings of the American Association for Cancer Research 43:639 (abstr 3174). Poster Presentation, 2002.
22. Kim J, Troncoso P, Menter DG, Babaian RJ, Pisters LL, Pettaway CA, Wood CG, Taylor RJ, Thall PF, Johnson K, Cavazos C, Lippman SM, Logothetis CJ, Lieberman R, Sabichi AL. A preprostatectomy clinical model testing chemopreventive agents in prostate cancer. The 10th SPORE Investigators’ Workshop (abstr 15). Poster Presentation, 2002.
23. 4. Li Z, Amato R, Papandreou C, Pagliaro L, Kim J, Millikan R, Loggins-Coffman J, Perez C, Logothetis C, Daliani D. Phase II study of thalidomide for patients with metastatic renal cell carcinoma (MRCC) progressing after interleukin-2 (IL-2)-based therapy (Rx). Proceedings of the American Society of Clinical Oncology 20:180a (abstr 717). Poster Presentation, 2001.
24. Kim J, Millikan RE, Pagliaro L, Tu SM, Daliani DD, Papandreou C, Amato RJ, Logothetis C. Phase II trials of continuous intravenous infusion of interleukin-2 for refractory metastatic urothelial carcinoma. Proceedings of the American Society of Clinical Oncology 19:353a (abstr 1388). Poster Presentation, 2000.
25. 1. Kim J, Diaz M, Logothetis CJ, Hoosein NM. Expression of prolactin and prolactin receptors by human prostatic cancer cell lines, PC-3, DU-145 and LNCaP. Proceedings of the American Association for Cancer Research 39:110 (abstr 746), Poster Presentation, 1998.
26. Kim J, Finn L, Hodges S, Hoosein N, Deftos L, Logothetis C. Neuroendocrine marker as a predictor of early progression in androgen-independent prostate cancer (AIPC). ). Proceedings of the American Society of Clinical Oncology 34:315a (abstr 1213). Poster Presentation, 1998.
27. Parker PA, Davis JW, Latini DL, Baum G, Wang X, Ward JF, Kuban D, Frank SF, Lee AK, Logothetis CJ, Kim J. Associations between uncertainty, anxiety, and quality of life in men with favorable-risk prostate cancer on active surveillance: 2 1/2 year follow-up. ASCO Genitourinary Cancers Symposium. Submitted.

Book Chapters

1. Patterson ML, Davis JW, Kim J, Hoffman KE, Osai WE, Kuban DA. Guidelines for Long-term Management of Genitourinary Cancer Survivors. In: The MD Anderson Cancer Center Survivorship Textbook. In Press.
2. Logothetis CJ, Troncoso P, Kim J, Davis JW, Kuban DA, Mathew P, Aparicio A. Neoplasms of the Prostate. In: Cancer Medicine, 8th. Peoples Medical Publishing House-USA: Shelton, CONN, 1228-54, 2010.
3. Zurita AJ, Ward JF, Kim J. Targeted therapy in prostate cancer. In: R Kurzrock, Markman (ed): Targeted Therapy in Cancer Humana Press USA, 2007, 289-304, 2008.
4. Kim J, Logothetis C. A biological framework for the development of therapy in prostate cancer. In: Progress in Anti-Cancer Chemotherapy. Springer-Verlag, 189-201, 2000.

Letters to the Editor

1. Kim J, Amos C, Logothetis C. Prostate Cancer Prevention: Does Caution Threaten Progress? New Eng J Med 365(24):2340, 12/2011. PMCID: PMC22168662.

Manuals, Teaching Aids, Other Teaching Publications

1. Online Video Education, Prostate Survivorship Course: Active Surveillance, 2012.
2. Kim J. Standard Operations Manual, Genitourinary Medical Oncology Serum Bank, 2000.
 

Other

1. UT MD Anderson Website and Local T.V. Video.

Grant & Contract Support

Title: High-throughput sequencing to identify novel prostate cancer susceptibility genes
Funding Source: NIH/NCI
Role: Co-Investigator
Duration: 7/1/2013 - 6/30/2018
 
Title: MD Anderson Cancer Center Moon Shot Program, Prostate Cancer. Toward integrated clinical-molecular model to identify aggressive prostate cancer and predict progression and prognosis in men with localized prostate cancer
Funding Source: MD Anderson Cancer Center
Role: Co-Investigator
Principal Investigator: Xifeng Wu
Duration: 2013 - 2016
 
Title: Cancer Prevention Agent Development Program: Early Phase Clinical Research
Funding Source: NIH/NCI
Role: Collaborator
Principal Investigator: Powel Brown
Duration: 9/1/2012 - 8/31/2019
 
Title: Patient education for prostate cancer patients on active surveillance
Funding Source: Tex US TOO, Inc.
Role: Collaborator
Duration: 2011
 
Title: MD Anderson Cancer Center Prostate SPORE. Project 5: MicroRNA in Prostate Cancer Progression: Genetic Variation, Genotype-Phenotype Correlation, and Circulating Biomarker
Funding Source: NIH/NCI
Role: Clinical Co-Leader
Principal Investigator: Christopher Logothesis
Duration: 9/2/2009 - 8/31/2014
 
Title: The University of Texas M.D. Anderson SPORE in prostate cancer, Specimen Core C
Funding Source: NIH/NCI
Role: Collaborator
Duration: 9/2/2009 - 8/14/2014
 
Title: A randomized controlled trial evaluating the tissue effects of preoperative finasteride versus placebo for patients with clinically organ-confined prostate cancer
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 2007 - 2013
 
Title: An animal model for adverse progression of prostate cancer, The University of Texas MD Anderson SPORE in Prostate Cancer
Funding Source: NIH/NCI
Role: Co-Investigator
Duration: 1/12/2006 - 12/31/2007
 
Title: Collaboration between Royal Marsden NHS Trust/Institute of Cancer Research and The University of Texas MD Anderson Cancer Center through Establishment of Postdoctoral Fellowship, 1-Selenomethionine, alpha-tocopherol, and oxidative stress: their effects on cell death and gene regulation in prostate cells
Funding Source: The Kadoorie Charitable Foundation
Role: Collaborator
Duration: 2003 - 2007
 
Title: Differential gene expression induced by antioxidants, National Cancer Institute
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 2003 - 2007
 
Title: Modulation of the arachidonic acid cascade by l-selenomethionine and alpha-tocopherol in normal and malignant prostate cells, The University of Texas MD Anderson SPORE in Prostate Cancer Career Development Award
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 2003 - 2005
 
Title: The University of Texas MD Anderson SPORE in Prostate Cancer, Tissue Resource & Pathology Core
Funding Source: NIH/NCI
Role: Co-Investigator
Duration: 2001 - 2007
 
Title: Fingerprinting the circulating pool of tumor-related antibodies in cancer patients: Translation into clinical application
Funding Source: Clinician Investigator Career Development Program
Role: Principal Investigator
Duration: 2001 - 2004
 
Title: Development of in situ expression of the 16K fragment of prolactin with antiangiogenic activity for prostate cancer treatment.
Funding Source: Institutional Research Grant Award
Role: Principal Investigator
Duration: 2001 - 2003
 
Title: Fingerprinting the circulating pool of tumor-related antibodies from prostate cancer patients, CaP CURE Research Award
Funding Source: CaP Cure Research Award
Role: Co-Investigator
Duration: 2001 - 2002
 
Title: A feasibility study of l-selenomethionine and alpha-tocopherol in prostate cancer
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 2000 - 2005

Last updated: 4/9/2014